We are in the midst of the COVID-19 pandemic, which has seen numerous randomized
clinical trials (RCTs)(referred to as trials in this document) of similar interventions, but with …

Objective To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in
COVID-19 patients. Data Sources A systematic review of the MEDLINE and Scopus …

Purpose COVID-19 is characterized by dysregulated immune response, respiratory failure
and a relevant mortality rate among hospitalized patients. Interleukin-6 (IL-6) is involved in …

Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …

Summary Objectives Multiple RCTs of interleukin-6 (IL-6) inhibitors in COVID-19 have been
published, with conflicting conclusions. We performed a meta-analysis to assess the impact …

(IL-6), based on the hypothesis that SARS-CoV-2 creates injury to the lung and other organs
in part through activation of cytokine and downstream proinflammatory networks. While …

Abstract Background Interleukin‐1 (IL‐1) blocking agents have been used for treating
severe coronavirus disease 2019 (COVID‐19), on the premise that their immunomodulatory …

Background: Interleukin-6 (IL-6) is known to be detrimental in coronavirus disease 2019
(COVID-19) because of its involvement in driving cytokine storm. This systematic review and …

Introduction Preliminary studies showed that coronavirus disease 2019 (COVID-19) disrupts
body immune system, including dysregulation of cytokine interleukin-6 (IL-6). IL-6 inhibitors …

Background It has been reported that people with COVID‐19 and pre‐existing
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …